Abstract:Kaixuan Zhao, 1, &ast Siqi Pu, 2, &ast Liyun Sun, 1 Dongmei Zhou 1 1 Dermatology Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 10010, People's Republic of China; 2 School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Liyun Sun, Dermatology Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, 23 Art Musuem Back Street, Dongcheng District, Beijing, 100010, People's Republic of China, Email Dongmei Zhou, Dermatology Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, 23 Art musuem Back Street, Dongcheng District, Beijing, 100010, People's Republic of China, Email Purpose: In this study, we aimed to report the biological characteristics of the first successful synthesis of gentiopicroside-loaded chitosan nanoparticles and to evaluate the therapeutic effects and preliminary mechanisms of gentiopicrin-loaded chitosan on psoriasis-like cell and mouse models. Methods: Gentiopicroside-loaded chitosan nanoparticles (CHI-GEN) were prepared, and their biological characteristics were evaluated. HaCaT keratinocytes were stimulated with TNF-α to establish a psoriatic keratinocyte model. MTT assay and flow cytometry were used to measure cell viability and apoptosis, respectively. mRNA levels of K17, VEGF A, and IL-6 and IL-23A were detected using qRT-PCR. These tests were used to preliminarily assess the effects of CHI-GEN on keratinocyte proliferation and inflammation. Imiquimod was used to construct a psoriasis-like mice model. The severity of psoriasis was scored based on the psoriasis area severity index (PASI), H&E staining was used to observe the histological changes and the level of inflammation and cell proliferation of skin lesions was evaluated by measuring the mRNA levels of K17, IL-23A, and IL-17A using qRT-PCR. Results: The average particle size of CHI-GEN nanoparticles was approximately 100 nm, and the zeta potential was 2.69 ± 0.87 mV. The cumulative release was 67.2% in solutions of pH 5.5 at 24 h. GEN reduced TNF-α-induced excessive proliferation of HaCaT keratinocytes and downregulated mRNA levels of K17, VEGF A, and inflammatory cytokines IL-6 and IL-23A, which was more obvious in the CHI-GEN treatment group. Additionally, CHI-GEN significantly improved the severity of skin lesions in psoriasis-like mice and downregulated the mRNA expressions of IL-6, IL-23A, and IL-17A in mice skin lesions. Conclusion: In conclusion, we successfully prepared gentiopicrin-chitosan nanoparticles. Our results show that these nanoparticles have anti-psoriasis activity, inhibits keratinocyte proliferation and improves symptoms in psoriasis model mice and can be used to develop an effective strategy for the treatment of psoriasis. Keywords: chitosan, nanoparticles, gentiopicroside, chitosan-loaded nano cream for external use, psoriasis, proliferation and inflammation Psoriasis is a chronic inflammatory skin disease characterized by erythema, scaling, and thickness. It is characterized by excessive proliferation and abnormal differentiation of epidermal keratinocytes, as well as increased infiltration of immune cells and intracutaneous angiogenesis. 1,2 The disease course is long and prone to relapse which seriously affects the physical and mental health of patients. Psoriasis may also induce various complications, such as psoriatic arthritis, metabolic syndrome, non-melanoma skin cancer, and cardiovascular diseases. 3 In recent years, the incidence of this disease is on the rise, ranging from 0.09% to 11.43% in different countries. About 125 million people suffer from this disease worldwide, bringing a serious economic burden to society and the families of patients. 4 Psoriasis is a multigenic and environmentally induced autoimmune disease, whose pathogenesis is complex and has not been fully elucidated. 1 Keratinocytes and infiltrating immune cells play a key role in the pathogenesis and development of psoriasis. 5 In psoriatic lesions, immune cells secrete various cytokines to stimulate keratinocytes leading to their excessive proliferation, which in turn responds to these cytokines by producing many pro-inflammatory cytokines to maintain and amplify the inflammatory response. 6–8 Therefore, drugs that inhibit keratinocyte overproliferation and inflammation have the potential for the treatment of psoriasis. Although biologics such as methotrexate, cyclosporine, UVB irradiation, and topical drugs have achieved certain clinical effica -Abstract Truncated-

Geniposide alleviates imiquimod-induced psoriasis-like skin lesions in mice via inhibition of angiogenesis

L-Theanine Alleviates IMQ-Induced Psoriasis Like Skin Inflammation by Downregulating the Production of IL-23 and Chemokines

Pretreatment with geniposide mitigates myocardial ischemia/reperfusion injury by modulating inflammatory response through TLR4/NF-?13 pathway

Geniposide ameliorates psoriatic skin inflammation by inhibiting the TLR4/MyD88/NF-κB p65 signaling pathway and MMP9

Geniposide alleviates choroidal neovascularization by downregulating HB-EGF release from RPE cells by downregulating the miR-145-5p/NF-κB axis

Apigenin ameliorates imiquimod-induced psoriasis in C57BL/6J mice by inactivating STAT3 and NF-κB

Topical application of imatinib mesylate ameliorated psoriasis‐like skin lesions in imiquimod‐induced murine model via angiogenesis inhibition

RasGRP1 influences imiquimod-induced psoriatic inflammation via T-cell activation in mice

Geniposide Inhibited Endothelial-Mesenchymal Transition Via the Mtor Signaling Pathway in a Bleomycin-Induced Scleroderma Mouse Model.

Selenium-Rich Yeast Peptide Fraction Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis in Mice by Inhibiting Inflammation via MAPK and NF-kappa B Signaling Pathways

Periplogenin induces necroptotic cell death through oxidative stress in HaCaT cells and ameliorates skin lesions in the TPA- and IMQ-induced psoriasis-like mouse models

Anti-Angiogenic Efficacy of PSORI-CM02 and the Associated Mechanism in Psoriasis In Vitro and In Vivo

Selenium-Rich Yeast Peptide Fraction Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis in Mice by Inhibiting Inflammation via MAPK and NF-κB Signaling Pathways

Tetrastigma hemsleyanum polysaccharides alleviate imiquimod-induced psoriasis-like skin lesions in mice by modulating the JAK/STAT3 signaling pathway

Gentiopicroside-Loaded Chitosan Nanoparticles Inhibit TNF-α-Induced Proliferation and Inflammatory Response in HaCaT Keratinocytes and Ameliorate Imiquimod-Induced Dermatitis Lesions in Mice

Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice

Paeoniflorin Inhibits Skin Lesions in Imiquimod-Induced Psoriasis-Like Mice by Downregulating Inflammation.

An Emerging Role of Proanthocyanidins on Psoriasis: Evidence from a Psoriasis-Like Mouse Model

Quercetin Ameliorates Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Via the NF-κB Pathway.

The Protective Effects of 18Β-Glycyrrhetinic Acid on Imiquimod-Induced Psoriasis in Mice Via Suppression of Mtor/stat3 Signaling

Isogarcinol Extracted from Garcinia Mangostana L. Ameliorates Imiquimod-Induced Psoriasis -Like Skin Lesions in Mice